Clinical Trial Update: ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating 12 months versus 6 months of HER2-targeted therapy for HER2-positive breast cancer patients who achieved pathologic complete res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Herceptin (trastuzumab) (trastuzumab)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8 | Phase 3 | Status: RECRUITING